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Strategies for Modulating T Cell Responses in Autoimmunity and Infection
T-cell differentiation and effector functions are shaped by the integration of different signals from the environment. The process initiated when the T-cell receptor is engaged is then modulated by activating (costimulatory molecules and cytokines) and inhibitory (checkpoint receptors and cytokines) signals, which have a direct impact on the development or function of effector and/or regulatory T (Treg) cells (1, 2) . In pre-clinical human or animal studies, the manipulation of T-cell function has been attempted via numerous different approaches, including (i) manipulation of metabolism (3), (ii) modulation of autophagy, (iii) regulation of epigenetic processes (4), (iv) agonistic or antagonistic therapies engaging cellular receptors (5) , (v) the use of cytokines/chemokines to skew immune response profiles, (vi) the expansion/depletion of certain cell type (i.e., depletion of Tregs or expansion of effector T cells specific for a certain pathogen) (6) , and (vii) the use of diverse immunomodulating natural or synthetic compounds that could regulate any of the above mentioned aspects of the immune response (7) , among others. The goal of the current Research Topic is to highlight some of these approaches and to focus on the diverse ways of modulating T-cell function or frequency in health and disease.
Within this eBook, some authors addressed the potential of diverse strategies, such as manipulating metabolic pathways, autophagy processes, and/or modification of the redox cellular milieu with an impact on T-cell function. Chemokines and/or cytokines themselves could serve as therapeutic targets. In their work, Ushio et al. used a murine model for Sjögren's syndrome as a way to understand the role of CCL22 in this autoimmune disease. They observed that CCL22-producing tissue-resident macrophages may control autoimmune lesions by enhancing the migratory capacity of CD4+ T cells to the affected tissue as well as by inducing IFN-γ production of T cells. Another example of how cytokines and their downstream effects could be used as targets for immunotherapy is addressed in the work of Min et al.. The authors clearly showed the relevance of the Type I IFN/IL-10 axis in the induction of antigen-specific T-cell function and the generation of T-cell memory in a mouse model for scrub typhus, an infectious disease caused by the intracellular bacteria Orientia tsutsugamushi. Their work contributes to a better understanding of the mechanisms behind the short longevity of antigen-specific adaptive immunity observed during this human infection (8) .
A different approach proposed by some authors consists of expanding effector cells or limiting the function of regulatory cells with the aim to improve immune responses against pathogens. Salido et al. expanded in vitro CD8+ T cells from HIV+ subjects on combination antiretroviral therapy (cART). Their ultimate goal was to explore new strategies aimed at modulating CD8+ T lymphocytes to achieve functional cure of HIV infections. They observed that expanded cells were polyfunctional, skewed toward an effector phenotype, and that PD-1 expression was clustered in HIV-specific effector memory CD8+ T cells, which had the highest cytokine-producing capacity. Antiviral activity was also enhanced in these cells, indicating that, despite being dampened in subjects on cART, the HIV-specific CD8+ T-cell response could be selectively stimulated and expanded in vitro. On the other hand, the work of Araujo Furlan et al. explored the role of Tregs during Trypanosoma cruzi infection and the impact of Treg frequency over pathology. They observed that massive accumulation of effector immune cells resulted in a diminished frequency of Tregs and inversely correlated with the magnitude of the immune response as well as with emergence of acute immunopathology. After transfer of Tregs, CD8+ T-cell function was affected and parasite control in blood and tissues was diminished, highlighting the relevance of Tregs over cytotoxic immunity against the parasite. Another important population of T cells that was reviewed by Shiromizu et al. consists of γδ T cells, whose role during autoimmunity and infection has been analyzed in depth in their work. They have also revised concepts about the mechanisms that modulate γδ T-cell function, giving the framework to consider the modulation of these cells as a tool to control pathological immune responses.
Collectively, the wide spectrum of original papers and reviews presented in this eBook have provided a comprehensive overview of potential strategies aiming to convert a pathological immune response into a protective one through the control or reprogramming of specific T-cell subsets. The insights outlined here will hopefully help shape future therapeutics for the treatment of infectious and autoimmune diseases.
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